Category

• Pipeline2
• Research1

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• Leber Hereditary Optic Neuropathy (lhon)2
• Clinical Trials1
• Injections1
• Retinitis Pigmentosa1
• Visual Acuity1

• Organizations: GenSight Biologics✕

Clear all

Pipeline

GenSight Biologics reports 4-year efficacy and safety data on LUMEVOQ for LHON

Latest results confirm 3-year safety and efficacy of one-time injection in unilateral- and bilateral-treated eyes.

Research

GenSight Biologics releases 3-year follow-up data on Lumevoq for LHON

REFLECT trial shows sustained efficacy and safety of bilateral injections.

Pipeline

GenSight Biologics releases 1-year data from phase 1/2 trial of RP treatment

PIONEER study shows favorable safety and efficacy results for GS030.